Skip to content

Asthma guidelines

TL;DR — Guidelines agree more than they disagree: confirm variable airflow where possible, assess both symptoms and future attack risk, use ICS-containing treatment, check technique/adherence before escalation, give a written action plan and review after attacks. The most consequential difference is the reliever pathway. GINA 2026 and UK BTS/NICE/SIGN 2024 prefer low-dose ICS–formoterol as anti-inflammatory reliever for adults/adolescents; the US NAEPP 2020 focused update endorses SMART for persistent asthma but retained older EPR-3 material outside six selected topics. Apply the current document for the patient’s jurisdiction, age, device, licensed formulation and access. A recommendation is not portable if the specified inhaler or diagnostic test is unavailable.

Current source set

Source Current document verified Scope and status
Global Initiative for Asthma GINA 2026 Strategy Report and 2026 Summary Guide Global evidence strategy; annual update; not a jurisdictional regulator
UK BTS/NICE/SIGN NG245 Joint diagnosis, monitoring and chronic management guideline, published November 2024; amended November 2025
United States NAEPP 2020 Focused Updates Nineteen recommendations in six priority areas; supplements rather than replaces EPR-3
Australia Australian Asthma Handbook v3.0 Major update published September 2025; primary-care focused
Resource-limited primary care WHO PEN 2020 Essential NCD protocols and core technology/medicine approach

Official-source currency was rechecked 2026-08-30. Product licenses, reimbursement and emergency protocols must still be checked locally.

What a guideline is—and is not

GINA is a regularly updated global strategy informed by literature review and expert synthesis. National guidelines may use formal evidence-to-decision methods, integrate cost and licensure, and update less often. The published GINA rationale explains the move away from SABA-only treatment and toward risk reduction (Reddel 2022, PMID 34658302).

NAEPP 2020 is deliberately focused: intermittent ICS, LAMA, indoor allergen mitigation, immunotherapy, FeNO and bronchial thermoplasty. It should be read alongside EPR-3 for topics not updated (Cloutier 2020, PMID 33270095; PMID 17983880).

Different recommendations can therefore reflect:

  • different publication dates and evidence cutoffs;
  • different questions, populations and comparators;
  • regulatory availability of a specific dose/device;
  • formal cost-effectiveness and health-system constraints;
  • different tolerance for indirect pediatric evidence;
  • a complete strategy versus a focused update.

Comparison articles document real overlap and divergence between GINA and NAEPP, especially mild disease, SMART and age thresholds (Chipps 2022, PMID 34718214). Apparent contradiction should trigger examination of the exact population and formulation, not selection of whichever table is most convenient.

Diagnostic convergence

All major contemporary frameworks start with a compatible pattern of variable respiratory symptoms and seek objective evidence of variable expiratory airflow.

Element GINA 2026 BTS/NICE/SIGN NG245 NAEPP/EPR-3
Initial evidence Spirometry/reversibility or documented variability Sequenced objective algorithm by age Spirometry with reversibility in suitable ages
FeNO Supports type-2 inflammation/diagnosis; not standalone Incorporated into adult and pediatric sequence Conditional adjunct when diagnosis uncertain
Normal initial tests Repeat during symptoms or use alternative variability/challenge evidence Follow specified sequence/referral Reconsider timing and alternatives
Preschool Probability, response and repeated review Age-under-5 trial/review pathway Recurrent-wheeze and age-specific framework
Occupational Ask relation to work and refer promptly Explicit work/holiday questions and specialist referral Exposure history and serial assessment

Diagnostic guidance has changed materially across eras, particularly around FeNO and test sequence (Drake 2019, PMID 32026404). The ERS pediatric diagnostic guideline similarly emphasizes objective testing in children aged 5–16 and cautions against symptom-only diagnosis (Gaillard 2021, PMID 33863747).

ATS FeNO guidance provides interpretive ranges but insists that FeNO be understood in clinical context; atopy, ICS use, smoking, infection and technique affect it (Dweik 2011, PMID 21885636).

The reliever divide

GINA Track 1

GINA’s preferred adult/adolescent track uses low-dose ICS–formoterol as reliever at lower steps and as maintenance-and-reliever therapy (MART) when maintenance is needed. The principle is that worsening symptoms trigger both rapid bronchodilation and anti-inflammatory treatment (Levy 2023, PMID 36754956).

GINA’s alternative track uses SABA or an ICS–SABA approach with scheduled ICS-containing controller as indicated. It requires confidence that adherence will prevent SABA-only exposure.

BTS/NICE/SIGN

NG245 recommends as-needed low-dose ICS/formoterol anti-inflammatory reliever (AIR) for newly diagnosed asthma from age 12, and low-dose MART for highly symptomatic presentation or severe attack. Its current online update notes formulation-specific licensing, including a November 2025 pediatric MART amendment (NG245 recommendations).

NAEPP

NAEPP conditionally recommends SMART with ICS–formoterol as preferred controller/reliever for moderate-to-severe persistent asthma from age 4, with strength and certainty varying by age. For mild persistent asthma at age 12+, it allows daily low-dose ICS plus SABA or concomitant as-needed ICS and SABA; it did not evaluate the same mild-asthma as-needed ICS–formoterol question later adopted by GINA (Murphy 2021, PMID 34432620).

Question Why recommendations differ
SABA-only at the lowest step GINA reassessed safety and later mild-asthma trials; NAEPP asked selected focused questions
Minimum age for MART Direct evidence, formulation dose and regulator decisions differ
ICS–SABA reliever Evidence and product availability matured after some guideline cutoffs
Maximum daily actuations Molecule, dose, device and age are not interchangeable

Reviews of anti-inflammatory reliever implementation emphasize formulary change, clinician education and patient explanation; prescribing a combination inhaler without explaining its dual role can create new errors (Zaeh 2024, PMID 38336438; Krings 2024, PMID 38237858).

Stepwise care: shared logic

Step Required action before/alongside medication
Confirm Demonstrate variable airflow where possible and document basis
Assess Symptoms, attacks, reliever use, lung function and adverse effects
Optimize Technique, adherence, smoking/exposure, comorbidity and access
Treat ICS-containing regimen matched to age and current guidance
Reassess Response over a defined interval using the same outcome measures
Step down After sustained control, reduce cautiously while preserving ICS protection
Refer Diagnostic uncertainty, recurrent severe attacks, high-dose/systemic steroid or biologic need

Asthma control and exacerbation definitions require distinct measurement; symptom control does not erase future risk (Reddel 2009, PMID 19535666).

Selected topic comparisons

FeNO

  • GINA: adjunct for type-2 inflammation, diagnosis and selected treatment decisions; not a rule-out test.
  • NAEPP: conditional use as an adjunct when diagnosis remains uncertain and selected monitoring contexts; recommends against FeNO alone to assess control or predict attacks.
  • BTS/NICE/SIGN: places FeNO within age-specific diagnostic sequences.

LAMA

NAEPP conditionally prefers adding LABA to ICS over LAMA when LABA is usable, and conditionally permits LAMA add-on to ICS/LABA for uncontrolled persistent asthma. GINA and NG245 place LAMA later, with modest average lung-function/attack benefit and less symptom improvement.

Allergen mitigation and immunotherapy

NAEPP recommends multicomponent allergen-specific mitigation when symptoms relate to confirmed indoor allergens, not routine untargeted packages. It conditionally recommends subcutaneous immunotherapy for selected controlled mild-to-moderate allergic asthma and recommends against sublingual immunotherapy specifically as asthma treatment.

ARIA and national rhinitis guidance address the upper airway and may influence asthma burden, but rhinitis treatment recommendations should not be mistaken for asthma-controller evidence (Bousquet 2020, PMID 31627910).

Exercise-induced bronchoconstriction

ATS recommends pre-exercise SABA and adds controller strategies when symptoms persist; objective exercise/hyperpnea testing is preferable when diagnosis affects competition, occupation or long-term treatment (Parsons 2013, PMID 23634861).

Severe asthma

ERS/ATS severe-asthma guidance addresses anti-IL-5, anti-IL-4Rα, tiotropium and macrolides in phenotyped uncontrolled disease after optimization (Holguin 2020, PMID 31558662). GINA’s annually updated severe-asthma guide additionally reflects newer biologics and practical eligibility.

The 2026 CHEST guideline compares biologic choices in adults, but biologic selection still depends on local indication, biomarkers, comorbidity, dosing and payer criteria (Oberle 2026, PMID 41005695).

Acute pediatric critical asthma

Acute pathways are not fully covered by chronic guidelines. The AARC/PALISI guideline addresses pediatric critical asthma respiratory support and adjuncts; local emergency/ICU protocols govern immediate dosing and escalation (White 2025, PMID 40323974).

Pregnancy

Guidelines broadly recommend continuing effective ICS-containing treatment and treating attacks promptly. The older NAEPP pregnancy update remains a cited US source but predates current reliever strategies and biologics (PMID 15637545). Current obstetric, product-specific and severe-asthma guidance must supplement it.

Resource-limited settings

A theoretically optimal regimen that cannot be obtained is not effective care. WHO reports that in low- and lower-middle-income countries, peak-flow meters were available in 25% of surveyed countries, bronchodilator inhalers in 60% and steroid inhalers in 40% (WHO chronic respiratory disease programme).

WHO PEN prioritizes diagnosis, inhaled bronchodilator, low-dose beclometasone and acute systemic steroids within primary-care capacity. GINA explicitly asks clinicians to adapt to available medicines and local regulation rather than reproduce its tables without an access plan.

Minimum safe system components are:

  1. reliable access to quality-assured ICS-containing inhalers;
  2. spacer access or locally appropriate spacer solution;
  3. trained observation of technique;
  4. written/pictorial action plans in relevant languages;
  5. oxygen and acute bronchodilator capacity;
  6. referral/transport pathways for severe attacks;
  7. continuity so controller refills do not depend on recurrent emergencies.

Guideline implementation gap

Conflicting or changing tables can confuse primary care, particularly when recommendations are detached from their evidence questions (Keeley 2018, PMID 29317387). The solution is a locally governed pathway with version control, not clinician memorization of every international document.

Implementation control Verification metric
Embed current age-specific pathway Version/date visible in order set
Restrict reliever choices to validated formulations Product and max-use instructions match guideline
Require objective diagnosis field Proportion with spirometry/variability evidence or reason unavailable
Technique teach-back Device-specific competency documented
Attack follow-up trigger Visit completed within defined interval
OCS surveillance Courses and cumulative dose visible across settings
Written action plan Current plan accessible to patient and care team

GINA’s evolution from a classification document to a risk-oriented global strategy was driven partly by implementation needs in primary care (Reddel 2015, PMID 26224549). Historical comparisons show why naming the edition matters: “US versus European guidance” is not a stable distinction (Reddy 2014, PMID 24162904).

How to resolve a bedside disagreement

  1. Name the exact guideline, version and jurisdiction.
  2. Match age, severity, phenotype and treatment history to the recommendation population.
  3. Identify whether it is strong/conditional and the certainty of evidence.
  4. Check exact formulation, dose, device, license and payer access.
  5. Explain meaningful alternatives and uncertainty to the patient.
  6. Document the chosen outcome and reassessment interval.

The latest-looking source is not automatically best for every question. The GINA annual strategy may be most current for relievers; a formal national guideline may better address local diagnostics/cost; a specialty guideline may better address FeNO, exercise or severe asthma.

Open questions

  • Can guidelines converge on a shared core with machine-readable jurisdictional modules?
  • How quickly should national bodies update after practice-changing reliever trials?
  • Which diagnostic algorithms are accurate and affordable when spirometry, FeNO or challenge testing is scarce?
  • How should environmental footprint be weighed without compromising device competence and control?
  • Which implementation metrics predict fewer deaths rather than better documentation?

References

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2026. Official report, accessed 2026-08-30.
  2. BTS, NICE and SIGN. Asthma: diagnosis, monitoring and chronic asthma management. NG245. 2024, amended 2025. Official guideline, accessed 2026-08-30.
  3. NAEPP Coordinating Committee. 2020 Focused Updates to the Asthma Management Guidelines. Official NHLBI report, accessed 2026-08-30.
  4. National Asthma Council Australia. Australian Asthma Handbook v3.0. 2025. Official handbook, accessed 2026-08-30.
  5. World Health Organization. WHO package of essential noncommunicable disease interventions for primary health care. 2020. Official publication, accessed 2026-08-30.
  6. Reddel HK, et al. GINA Strategy 2021: executive summary and rationale. Eur Respir J. 2022. PMID 34658302
  7. Levy ML, et al. Key recommendations for primary care from GINA 2022. NPJ Prim Care Respir Med. 2023. PMID 36754956
  8. Cloutier MM, et al. Managing asthma in adolescents and adults: NAEPP 2020 update. JAMA. 2020. PMID 33270095
  9. Chipps BE, et al. NAEPP 2020 and GINA 2021 differences, overlap and challenges. J Allergy Clin Immunol Pract. 2022. PMID 34718214
  10. National Asthma Education and Prevention Program. Expert Panel Report 3 summary. J Allergy Clin Immunol. 2007. PMID 17983880
  11. Gaillard EA, et al. ERS guideline for diagnosis in children aged 5–16. Eur Respir J. 2021. PMID 33863747
  12. Dweik RA, et al. ATS guideline: interpretation of FeNO. Am J Respir Crit Care Med. 2011. PMID 21885636
  13. Murphy KR, Solis J. NAEPP 2020: what is important for primary care. J Fam Pract. 2021. PMID 34432620
  14. Zaeh SE, et al. Implementing anti-inflammatory reliever strategies. J Allergy Clin Immunol Pract. 2024. PMID 38336438
  15. Krings JG, Beasley R. ICS-containing rescue therapy versus SABA alone. J Allergy Clin Immunol Pract. 2024. PMID 38237858
  16. Reddel HK, et al. Standardizing asthma control and exacerbation endpoints. Am J Respir Crit Care Med. 2009. PMID 19535666
  17. Bousquet J, et al. Next-generation ARIA guidelines. J Allergy Clin Immunol. 2020. PMID 31627910
  18. Parsons JP, et al. ATS guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013. PMID 23634861
  19. Holguin F, et al. ERS/ATS guideline for severe asthma. Eur Respir J. 2020. PMID 31558662
  20. Oberle AJ, et al. Biologic management in severe asthma for adults: CHEST guideline. Chest. 2026. PMID 41005695
  21. White BR, et al. AARC/PALISI guideline: pediatric critical asthma. Respir Care. 2025. PMID 40323974
  22. National Heart, Lung, and Blood Institute. Managing asthma during pregnancy: 2004 update. J Allergy Clin Immunol. 2005. PMID 15637545
  23. Keeley D, Baxter N. Conflicting asthma guidelines cause confusion in primary care. BMJ. 2018. PMID 29317387
  24. Reddel HK, et al. GINA strategy report: what is new for primary care. NPJ Prim Care Respir Med. 2015. PMID 26224549
  25. Reddy AP, Gupta MR. Management of asthma: current US and European guidelines. Adv Exp Med Biol. 2014. PMID 24162904
  26. Dubin S, et al. Update on asthma management guidelines. Mo Med. 2024. PMID 39421468
  27. British Thoracic Society, NICE, SIGN. Joint guideline summary of recommendations. Thorax. 2025. PMID 40274410
  28. Bateman ED, et al. Global strategy for asthma management and prevention: executive summary. Eur Respir J. 2008. PMID 18166595
  29. Reddel HK, et al. GINA 2014: a global strategy for a global problem. Int J Tuberc Lung Dis. 2014. PMID 24903781
  30. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on asthma management. Thorax. 2014. PMID 25323740
  31. Drake SM, Simpson A, Fowler SJ. Asthma diagnosis: the changing face of guidelines. Pulm Ther. 2019. PMID 32026404